Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Observational 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Non-small Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 30Drug Therapy 27Immunotherapy 25Surgical Procedures, Operative 22Carboplatin 22Nivolumab 21Immune Checkpoint Inhibitors 20pembrolizumab 18osimertinib 18atezolizumab 17Observation 17Radiotherapy 16Bevacizumab 15Cisplatin 14Afatinib 14Specimen Handling 13Gene Expression Profiling 13Erlotinib Hydrochloride 13lorlatinib 12Pemetrexed 12Magnetic Resonance Spectroscopy 11Ipilimumab 11Immunohistochemistry 11Biopsy 11durvalumab 10alectinib 10Paclitaxel 10Bronchoscopy 10Tomography, X-Ray Computed 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × taletrectinib × Thoracic × Clear all
NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

NCT07008287 2025-07-22

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡